Real-Life Data on the Effectiveness and Safety of Cefiderocol in Severely Infected Patients: A Case Series.
Acinetobacter baumannii
Cefiderocol
Critically ill patients
Gram-negative bacteria
Multidrug resistance
Pseudomonas aeruginosa
Journal
Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
13
11
2022
accepted:
08
02
2023
medline:
22
3
2023
pubmed:
22
3
2023
entrez:
21
3
2023
Statut:
ppublish
Résumé
Real-life data about cefiderocol use to treat extensively drug-resistant bacteria are scarce. We aim to report our early experience in patients with difficult-to-treat infections and limited therapeutic options. Patients treated with cefiderocol from March 2018 to April 2022 in a tertiary-care hospital in Spain were included. Demographic, clinical, and microbiological data were collected up to 90 days after the end of treatment or until death. Survival status was recorded at 30 and 90 days. Ten patients were included, seven of them critically ill. Ventilator-associated pneumonia (40%) and bacteremia (40%) were the main infections. Multidrug-resistant or extensively drug-resistant P. aeruginosa was the most frequently isolated pathogen (70%, of which six patients were infected with bacteria with difficult-to-treat resistance), followed by A. baumannii, E. coli, and A. xylosoxidans (10% each). Seven patients received combination therapy. Clinical and microbiological cures were achieved in 90% and 80% of patients, respectively. Two previously susceptible strains (20%) developed resistance to cefiderocol. Overall, 30-day and 90-day mortality rates were 10% and 50%, respectively, although two out of five patients died due to the infection. No serious adverse events were reported, except for one patient who developed thrombocytopenia. Cefiderocol seems to be an effective and safe rescue therapy for patients infected with difficult-to-treat pathogens, although there is a definite risk of the emergence of resistance.
Identifiants
pubmed: 36943617
doi: 10.1007/s40121-023-00776-3
pii: 10.1007/s40121-023-00776-3
pmc: PMC10029777
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1205-1216Informations de copyright
© 2023. The Author(s).
Références
World Health Organization. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. Geneva: WHO; 2017. p. 8–83.
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81. https://doi.org/10.1111/j.1469-0691.2011.03570.x .
doi: 10.1111/j.1469-0691.2011.03570.x
pubmed: 21793988
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–27. https://doi.org/10.1016/S1473-3099(17)30753-3 .
doi: 10.1016/S1473-3099(17)30753-3
pubmed: 29276051
Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169–83. https://doi.org/10.1093/cid/ciaa1478 .
doi: 10.1093/cid/ciaa1478
pubmed: 33106864
Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli. Drugs. 2019;79(3):271–89. https://doi.org/10.1007/s40265-019-1055-2 .
doi: 10.1007/s40265-019-1055-2
pubmed: 30712199
Aoki T, Yoshizawa H, Yamawaki K, Yokoo K, Sato J. Cefiderocol (S-649266), a new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship. Eur J Med Chem. 2018;155:847–68. https://doi.org/10.1016/j.ejmech.2018.06.014 .
doi: 10.1016/j.ejmech.2018.06.014
pubmed: 29960205
Syed YY. Cefiderocol: a review in serious gram-negative bacterial infections. Drugs. 2021;81(13):1559–71. https://doi.org/10.1007/s40265-021-01580-4 .
doi: 10.1007/s40265-021-01580-4
pubmed: 34427896
pmcid: 8383240
Yamano Y. In vitro activity of cefiderocol against a broad range of clinically important gram-negative bacteria. Clin Infect Dis. 2019;69(Suppl 7):S544–51. https://doi.org/10.1093/cid/ciz827 .
doi: 10.1093/cid/ciz827
pubmed: 31724049
pmcid: 6853761
Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria. Antimicrob Agents Chemother. 2017;62(1):e01454-e1517. https://doi.org/10.1128/AAC.01454-17 .
doi: 10.1128/AAC.01454-17
pubmed: 29061741
pmcid: 5740388
Kazmierczak KM, Tsuji M, Wise MG, Hackel M, Yamano Y, Echols R, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014). Int J Antimicrob Agents. 2019;53:177–84. https://doi.org/10.1016/j.ijantimicag.2018.10.007 .
doi: 10.1016/j.ijantimicag.2018.10.007
pubmed: 30395986
Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR) a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226–40. https://doi.org/10.1016/S1473-3099(20)30796-9 .
doi: 10.1016/S1473-3099(20)30796-9
pubmed: 33058795
Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21(2):213–25. https://doi.org/10.1016/S1473-3099(20)30731-3 .
doi: 10.1016/S1473-3099(20)30731-3
pubmed: 33058798
Babidhan R, Lewis A, Atkins C, Jozefczyk NJ, Nemecek BD, Montepara CA, et al. Safety and efficacy of cefiderocol for off-label treatment indications: a systematic review. Pharmacotherapy. 2022;42(7):549–66. https://doi.org/10.1002/phar.2704 .
doi: 10.1002/phar.2704
pubmed: 35611627
Meschiari M, Volpi S, Faltoni M, Dolci G, Orlando G, Franceschini E, et al. Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections. JAC-Antimicrobial Resist. 2021;3(4):1–5. https://doi.org/10.1093/jacamr/dlab188 .
doi: 10.1093/jacamr/dlab188
Rando E, Segala FV, Vargas J, Seguiti C, De Pascale G, Murri R, et al. Cefiderocol for severe carbapenem-resistant A. baumannii pneumonia: towards the comprehension of its place in therapy. Antibiotics. 2022;11(1):1–7. https://doi.org/10.3390/antibiotics11010003 .
doi: 10.3390/antibiotics11010003
Gatti M, Bartoletti M, Cojutti PG, Gaibani P, Conti M, Giannella M, et al. A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol. J Glob Antimicrob Resist. 2021;27:294–8. https://doi.org/10.1016/j.jgar.2021.10.014 .
doi: 10.1016/j.jgar.2021.10.014
pubmed: 34710630
König C, Both A, Rohde H, Kluge S, Frey O, Röhr A, et al. Cefiderocol in critically ill patients with multi-drug resistant pathogens: real-life data on pharmacokinetics and microbiological surveillance. Antibiotics. 2021;10(6):649. https://doi.org/10.3390/antibiotics10060649 .
doi: 10.3390/antibiotics10060649
pubmed: 34071700
pmcid: 8226704
Falcone M, Tiseo G, Nicastro M, Leonildi A, Vecchione A, Casella C, et al. Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant gram-negative infections in intensive care unit patients. Clin Infect Dis. 2021;72(11):2021–4. https://doi.org/10.1093/cid/ciaa1410 .
doi: 10.1093/cid/ciaa1410
pubmed: 32941593
Zingg S, Nicoletti GJ, Kuster S, Junker M, Widmer A, Egli A, et al. Cefiderocol for extensively drug-resistant gram-negative bacterial infections: real-world experience from a case series and review of the literature. Open Forum Infect Dis. 2020;7(6):1–4. https://doi.org/10.1093/ofid/ofaa185 .
doi: 10.1093/ofid/ofaa185
Bavaro DF, Belati A, Diella L, Stufano M, Romanelli F, Scalone L, et al. Cefiderocol-based combination therapy for “difficult-to-treat” gram-negative severe infections: real-life case series and future perspectives. Antibiotics. 2021;10(6):1–19. https://doi.org/10.3390/antibiotics10060652 .
doi: 10.3390/antibiotics10060652
Bodro M, Hernández-Meneses M, Ambrosioni J, Linares L, Moreno A, Sandoval E, et al. Salvage treatment with cefiderocol regimens in two intravascular foreign body infections by MDR gram-negative pathogens, involving non-removable devices. Infect Dis Ther. 2021;10(1):575–81. https://doi.org/10.1007/s40121-020-00385-4 .
doi: 10.1007/s40121-020-00385-4
pubmed: 33417231
pmcid: 7955010
Warner NC, Bartelt LA, Lachiewicz AM, Tompkins KM, Miller MB, Alby K, et al. Cefiderocol for the treatment of adult and pediatric patients with cystic fibrosis and Achromobacter xylosoxidans. Infections. 2021;73(7):e1754–7. https://doi.org/10.1093/cid/ciaa1847 .
doi: 10.1093/cid/ciaa1847
Oliva A, Ceccarelli G, De AM, Sacco F, Miele MC, Mastroianni CM, et al. Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii. J Glob Antimicrob Res. 2020;23:292–6. https://doi.org/10.1016/j.jgar.2020.09.019 .
doi: 10.1016/j.jgar.2020.09.019
Shionogi B.V. Fetcroja
European Committee on Antimicrobial Suspectibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 12.0. 2022. p. 1–110. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf . Accessed 15 Sept 2022.
Katsube T, Nicolau DP, Rodvold KA, Wunderink RG, Echols R, Matsunaga Y, et al. Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia. J Antimicrob Chemother. 2021;76(11):2902–5. https://doi.org/10.1093/jac/dkab280 .
doi: 10.1093/jac/dkab280
pubmed: 34383901
pmcid: 8521398
Karakonstantis S, Rousaki M, Kritsotakis EI. Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance. Antibiotics. 2022;11(6):723. https://doi.org/10.3390/antibiotics11060723 .
doi: 10.3390/antibiotics11060723
pubmed: 35740130
pmcid: 9220290
Bleibtreu A, Dortet L, Bonnin RA, Wyplosz B, Sacleux SC, Mihaila L, et al. Susceptibility testing is key for the success of cefiderocol treatment: a retrospective cohort study. Microorganisms. 2021;9(2):1–8. https://doi.org/10.3390/microorganisms9020282 .
doi: 10.3390/microorganisms9020282
Abdul-Aziz M, Alffenaar J, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46(6):1127–53. https://doi.org/10.1007/s00134-020-06050-1 .
doi: 10.1007/s00134-020-06050-1
pubmed: 32383061
pmcid: 7223855
Kufel WD, Abouelhassan Y, Steele JM, Gutierrez RL, Perwez T, Bourdages G, et al. Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis. J Antimicrob Chemother. 2022;77(10):2737–41. https://doi.org/10.1093/jac/dkac248 .
doi: 10.1093/jac/dkac248
pubmed: 35869778
Katsube T, Echols R, Wajima T. Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin. Clin Infect Dis. 2019;69(Suppl 7):S552–8. https://doi.org/10.1093/cid/ciz828 .
doi: 10.1093/cid/ciz828
pubmed: 31724042
pmcid: 6853762
Wei X, Naseer S, Weinstein EA, Iarikov D, Nambiar S, Reynolds KS, et al. Cefiderocol dosing for patients receiving continuous renal replacement therapy. Clin Pharmacol Ther. 2022;112(5):1004–7. https://doi.org/10.1002/cpt.2703 .
doi: 10.1002/cpt.2703
pubmed: 35792715
Wenzler E, Butler D, Tan X, Katsube T, Wajima T. Pharmacokinetics, pharmacodynamics, and dose optimization of cefiderocol during continuous renal replacement therapy. Clin Pharmacokinet. 2022;61(4):539–52. https://doi.org/10.1007/s40262-021-01086-y .
doi: 10.1007/s40262-021-01086-y
pubmed: 34792787